Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3236)	2/4/2022 7:49:23 PM
From: BioBait	Read Replies (2) \| Respond to of 3557

2021 guesstimate Dupi 4b +50% +2b Eylea 8b +10% .8b Cov2 US +3b ROW +3b (possibly more but being conservative) Other 1b +20% +.2b. (Maybe libtayo does better?) On 2020 13b +9b = 22b ~70% product revenue increase P/E ratio of ~20%. Will not hold for long. __——_————_——— 2022 guesstimate Dupi 6.2 +33% +2b Eylea 9.4 +15% +1.4b Cov2 US +0 Other 1.4 +20% +.3b (Maybe libtayo does better?) On 2021 24.5 -7.5b COV2 + 3.7 = 20.7 ~22% product revenue increase